Efficacy of Paricalcitol in the Treatment of Secondary Hyperparathyroidism in Maintenance Hemodialysis Patients

被引：0
|
作者：
Ou, Santao [1 ]
机构：
[1] Southwest Med Univ, Affiliated Hosp, Luzhou, Peoples R China
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PUB129
引用
收藏
页码：920 / 920
页数：1
相关论文
共 50 条
  • [21] Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients
    Wacharee Seeherunvong
    Obioma Nwobi
    Carolyn L. Abitbol
    Jayanthi Chandar
    José Strauss
    Gastón Zilleruelo
    Pediatric Nephrology, 2006, 21 : 1434 - 1439
  • [22] Efficacy of intravenous alfacalcidol in the treatment of secondary hyperparathyroidism in patients on hemodialysis
    Gonzalez, M. T.
    Torregrosa, J. V.
    Colome, E.
    Mendia, A.
    Pavesi, M.
    NEPHRON CLINICAL PRACTICE, 2008, 108 (02): : C141 - C147
  • [23] TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN MAINTENANCE HEMODIALYSIS-PATIENTS BY INTRAVENOUS CALCITRIOL
    JARA, A
    BOVER, J
    LLACH, F
    SEMINARS IN DIALYSIS, 1994, 7 (02) : 117 - 123
  • [24] Paricalcitol in Hemodialysis Patients with Secondary Hyperparathyroidism: A Long-Term Case Report
    Chen, Haoxiong
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 788 - 788
  • [25] Paricalcitol (Zemplar®) capsule controls secondary hyperparathyroidism in chronic hemodialysis patients.
    Llach, F
    Qiu, P
    Ross, EA
    Abboud, H
    Mere, CC
    Wojtak, A
    Hippensteel, R
    Williams, LA
    Block, G
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 198A - 199A
  • [26] PARICALCITOL TREATED HEMODIALYSIS PATIENTS UTILIZE LESS ERYTHROPOIETIN THAN PATIENTS NOT RECEIVING TREATMENT FOR SECONDARY HYPERPARATHYROIDISM [SHPT]
    Khan, Samina
    Marx, Steve
    Nissenson, Allen
    Johns, Beverly
    Audhya, Paul
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 55 (04) : A70 - A70
  • [27] Comparative Effectiveness of Paricalcitol versus Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
    Schumock, Glen T.
    Walton, Surrey M.
    Lee, Todd A.
    Marx, Steven E.
    Audhya, Paul
    Andress, Dennis L.
    NEPHRON CLINICAL PRACTICE, 2011, 117 (02): : C151 - C159
  • [28] Initial dosing of paricalcitol based on PTH levels in Hemodialysis patients with secondary hyperparathyroidism
    Mitsopoulos, Efstathios
    Zanos, Stavros
    Ginikopoulou, Eudoxia
    Kyriklidou, Parthena
    Meimaridou, Dafni
    Sakellariou, Georgios
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 48 (01) : 114 - 121
  • [29] BASELINE CHARACTERISTICS OF SUBJECTS IN IMPACTSHPT: A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PARICALCITOL AND CINACALCET IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM
    Ketteler, Markus
    Martin, Kevin
    Cozzolino, Mario
    Goldsmith, David
    Sharma, Amit
    Wolf, Myles
    Khan, Samina
    Amdahl, Michael
    Dumas, Emily
    Audhya, Paul
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2011, 57 (04) : A52 - A52
  • [30] TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN MAINTANENCE HEMODIALYSIS PATIENTS: A RANDOMISED CLINICAL TRIAL COMPARING PARICALCITOL, CALCITRIOL AND SINACALCET
    Sezer, Siren
    Tutal, Emre
    Bal, Zeynep
    Ozelsancak, Ruya
    Demirci, Bahar Gurlek
    Torun, Dilek
    Acar, F. Nurhan Ozdemir
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 509 - 510
12345